Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP

被引：0
作者：
Hisaharu Shikata
Yoshihiro Yakushijin
Jun Yamanouchi
Taichi Azuma
Masaki Yasukawa
机构：
[1] Ehime University Graduate School of Medicine,Department of Bioregulatory Medicine, Ehime University Hospital
[2] Ehime University Graduate School of Medicine,Cancer Center, Ehime University Hospital
来源：
International Journal of Clinical Oncology | 2014年 / 19卷
关键词：
Hematological nadir; Febrile neutropenia (FN); G-CSF prophylaxis; R-CHOP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：178 / 185
页数：7
相关论文
共 49 条
  • [41] 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
    Araie, Hiroaki
    Sakamaki, Ippei
    Matsuda, Yasufumi
    Tai, Katsunori
    Ikegaya, Satoshi
    Itoh, Kazuhiro
    Kishi, Shinji
    Oiwa, Kana
    Okura, Miyuki
    Tasaki, Toshiki
    Hosono, Naoko
    Ueda, Takanori
    Yamauchi, Takahiro
    [J]. INTERNAL MEDICINE, 2017, 56 (18) : 2407 - 2413
  • [42] Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma
    Yamauchi, Takahiro
    Matsuda, Yasufumi
    Takai, Mihoko
    Tasaki, Toshiki
    Tai, Katsunori
    Hosono, Naoko
    Negoro, Eiju
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Kishi, Shinji
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    [J]. ANTICANCER RESEARCH, 2012, 32 (11) : 5051 - 5057
  • [43] Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
    Villacampa, Guillermo
    Dienstmann, Rodrigo
    Bosch, Francesc
    Abrisqueta, Pau
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2969 - 2978
  • [44] Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
    Zhang, Fangwen
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Kong, Fei
    Ren, Liangliang
    Zhang, Mingzhi
    [J]. BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 33 - 43
  • [45] Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
    Guillermo Villacampa
    Rodrigo Dienstmann
    Francesc Bosch
    Pau Abrisqueta
    [J]. Annals of Hematology, 2021, 100 : 2969 - 2978
  • [46] External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival
    Warnnissorn, Naree
    Kanitsap, Nonglak
    Niparuck, Pimjai
    Boonsakan, Paisarn
    Kulalert, Prapasri
    Limvorapitak, Wasithep
    Bhoopat, Lantarima
    Saengboon, Supawee
    Chantrathammachart, Pichika
    Puavilai, Teeraya
    Chuncharunee, Suporn
    [J]. HEMATOLOGY, 2022, 27 (01) : 1237 - 1245
  • [47] Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network
    Hohloch, Karin
    Lankeit, H. K.
    Zinzani, P. L.
    Scholz, C. W.
    Lorsbach, M.
    Windemuth-Kieselbach, C.
    Truemper, L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (08) : 1585 - 1592
  • [48] Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age
    Eyre, T. A.
    Martinez-Calle, N.
    Hildyard, C.
    Eyre, D. W.
    Plaschkes, H.
    Griffith, J.
    Wolf, J.
    Fields, P.
    Gunawan, A.
    Oliver, R.
    Djebbari, F.
    Booth, S.
    McMillan, A.
    Fox, C. P.
    Bishton, M. J.
    Collins, G. P.
    Hatton, C. S. R.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2019, 285 (06) : 681 - 692
  • [49] The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia
    Tadic, Ljiljana
    Marjanovic, Goran
    Macukanovic-Golubovic, Lana
    Krstic, Miljan
    Jevtovic-Stoimenov, Tatjana
    Kostov, Milos
    Smelcerovic, Zaklina
    Stojanovic, Mariola
    [J]. JOURNAL OF BUON, 2016, 21 (05): : 1259 - 1267
12345